Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Hodgkin's lymphoma (HL) is a prevalent cancer among individuals aged 15-39, characterized by a high cure rate in early stages but diminished efficacy in advanced stages. Innovative therapy is imperative to improve outcomes at all stages of the disease. Alfa Cytology boasts a dedicated scientific team poised to contribute to developing Hodgkin's lymphoma vaccines. Our expertise and commitment enable us to offer comprehensive support and tailored solutions in the pursuit of effective vaccination strategies against this form of lymphoma.
Hodgkin lymphoma (HL) is a B-cell lymphoma originating from lymphocytes, a type of white blood cell. It is characterized by multinucleated Reed-Sternberg cells (RS cells) in the patient's lymph nodes. These abnormal cells play a key role in the diagnosis of HL. Hodgkin's lymphoma comprises two primary types, classic Hodgkin's lymphoma and nodular lymphocyte-predominant Hodgkin's lymphoma. The two types can be further classified according to their histologic and cytologic characteristics.
Fig. 1 Hodgkin and Reed–Sternberg (HRS) cell-mediated immune escape. (Aldinucci, D., et al.; 2019)
Lymphoid malignancies were initially treated with conventional chemotherapy, but the therapy of lymphomas has been revolutionized with the advent of immunotherapy, particularly with the introduction of anti-CD20 monoclonal antibodies (moAb). CD20 is commonly expressed in NLP-HL, but its level of expression varies among cHL cases. Recent studies have shown that drugs targeting CD20 can be effective in treating NLP-HL, including advanced cases.
HL cancer vaccines are a form of immunotherapy, and these vaccines usually contain specific antigens, such as activated T and B cells to attack HL cells. By administering an HL cancer vaccine, the immune system's recognition and removal of cancer cells can be promoted, thereby inhibiting or reducing the development and metastasis of HL. Currently, research and trials of HL cancer vaccines are ongoing, aiming to validate their safety and efficacy further and explore their potential role in HL treatment.
Researchers are increasingly focusing on cancer vaccines as a means to prevent cancer or decrease its recurrence. Alfa Cytology, specializing in cancer vaccine development services, offers various cancer vaccine types to aid researchers in developing a vaccine for Hodgkin's Lymphoma. Alfa Cytology can provide you with cancer vaccine development services including, but not limited to the following.
Alfa Cytology prioritizes the safety and effectiveness of our vaccines. We provide a diverse array of adjuvant options tailored to bolster the vaccine's immunogenicity and stability. Our adjuvant formulations are customized to elicit sustained and robust immune responses in vivo. Moreover, we offer various cancer vaccine delivery systems, including protein-conjugated, virus-like particle (VLP), and liposomal systems, among others, ensuring precise delivery to target tissues or cells and eliciting desired immune responses in vivo.
Alfa Cytology works closely with our clients to provide comprehensive technical support and solutions from vaccine design to preclinical trials. Our goal is to foster lasting partnerships that advance the development and application of cancer vaccines. If you are interested in our services, please feel free to contact us.
Reference